$25m IPO envisioned for ‘magic mushrooms’ to treat depression

A healthcare investment firm that’s backing studies of “magic mushrooms” to treat depression raised $25m of capital…

…already in talks with banks about a potential listing in Canada next year, a step for which it seeks a valuation of $800m  or more, according to one of the people familiar with the matter.  After being shunned for decades, psilocybin as a possible medical treatment has seen a revival in the past couple of years. Studies published in 2012 by David Nutt and Robin Carhart-Harris of Imperial College London found that the psychedelic reduced activity in the medial pre-frontal cortex, which is hyperactive in depression, and also enhanced volunteers’ recollections of positive personal memories. Nutt is chair of Compass’s scientific advisory board …  A study in the Journal of Psychopharmacology said that just two or three experiences with the hallucinogenic drug helped a dozen long-term smokers quit, succeeding in a study where numerous other approaches failed.

Original Article (Business
$25m IPO envisioned for ‘magic mushrooms’ to treat depression
Artwork Fair Use: Eweht

Leave a Reply